Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:awardReceived |
gptkb:MIT_Technology_Review_Innovators_Under_35_(Xavier_Duportet)
|
| gptkbp:CEO |
gptkb:Xavier_Duportet
|
| gptkbp:collaboratesWith |
gptkb:INSERM
gptkb:Institut_Pasteur |
| gptkbp:country |
gptkb:France
|
| gptkbp:developedBy |
Eligobiotics
|
| gptkbp:focusesOn |
precision medicine
microbiome engineering |
| gptkbp:foundedIn |
2014
|
| gptkbp:founder |
gptkb:David_Bikard
gptkb:Xavier_Duportet |
| gptkbp:fundedBy |
gptkb:Khosla_Ventures
gptkb:Bpifrance gptkb:Plug_and_Play_Ventures gptkb:INSERM_Transfert_Initiative gptkb:Innogest_Capital gptkb:F-Prime_Capital gptkb:Seventure_Partners gptkb:Novo_Holdings |
| gptkbp:headquartersLocation |
gptkb:Paris,_France
|
| https://www.w3.org/2000/01/rdf-schema#label |
Eligo Bioscience
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableAchievement |
developed targeted antimicrobials
|
| gptkbp:technology |
CRISPR-based gene editing
|
| gptkbp:website |
https://www.eligo.bio/
|
| gptkbp:bfsParent |
gptkb:Seventure_Partners
|
| gptkbp:bfsLayer |
6
|